Lai Mei Pharmaceutical: Controlling Subsidiary Receives Drug Clinical Trial Approval Letter.

Lai Mei Pharmaceuticals announced that its holding subsidiary Sichuan Yingrui Pharmaceutical Technology Co., Ltd. independently developed the innovative anti-cancer drug "Nano Charcoal Iron Mixed Suspension Injection". It has obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the clinical trial of nano charcoal iron combined with standard radiotherapy in patients with solid tumors. Nano charcoal iron is a new generation of nano drugs developed on the basis of the company's product Nano Charcoal Mixed Suspension Injection. It uses Fe2+ as the effective anti-cancer ingredient, with nano charcoal as the carrier for Fe2+, exerting anti-cancer effects through regulating the iron death pathway.